Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Quiz|Articles|October 30, 2026
OncLive Weekly News Quiz (10/30/2026): Did You Miss Crucial Prostate, HNSCC, and Hematologic Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA approved talazoparib (Talzenna) plus enzalutamide (Xtandi) for adult patients with with homologous recombination repair (HRR) gene–mutated metastatic androgen pathway modulation–naive or –sensitive prostate cancer, based on data from the phase 3 TALAPRO-3 trial (NCT04821622). What hazard ratio for radiographic progression-free survival did the combination achieve vs placebo plus enzalutamide?
Advertisement
Related to this article
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.
The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.
Niraparib/Dostarlimab Plus CRT Displays Efficacy but Has Toxicity Concerns in Locally Advanced HNSCC
Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.
Advertisement
Advertisement
Trending on OncLive
1
Key Questions on ADC Selection, Sequencing, and Toxicity Management Across Breast Cancer Subtypes
2
Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer
3
Lirafugratinib Associated With More Mucocutaneous AEs After Prior ICIs in FGFR2-Altered CCA and Other Solid Tumors
4
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd
5